Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06361927
PHASE2
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-05-15
Completion Date
2025-07
Last Updated
2024-05-16
Healthy Volunteers
No
Conditions
Interventions
DRUG
SSGJ-707
bispecific antibody
Locations (1)
The Hunan Cancer Hospital
Changsha, Hunan, China